AKUMS DRUGS AND PHARMA L
AKUMS · General/Diversified · NSE
₹514
Current Market Price
Fair Value (DCF)
₹333
Margin of Safety
-35.2%
Updated 2d ago
YieldIQ Score
52/100
Piotroski F-Score
7/9
Economic Moat
Narrow
Confidence
44%
ROE
—
Debt/Equity
0.03
WACC
11.1%
Market Cap
₹7,874 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
11.7%
Return on capital employed
EV / EBITDA
13.3×
Enterprise multiple
Debt / EBITDA
0.2×
Leverage vs earnings
Interest Coverage
12.4×
EBIT covers interest
Current Ratio
2.55×
Short-term liquidity
Asset Turnover
0.99×
Revenue per ₹ of assets
Revenue CAGR (3Y)
3.7%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹514.3
Bear case
₹202.57
MoS -153.9%
Base case
₹333.47
MoS -54.2%
Bull case
₹418.91
MoS -22.8%
Ratio Trends
AKUMS · last 4 annual periods
ROE
11.0%
ROCE
16.8%
Operating Margin
—
Debt / Equity
0.03×
PE
—
EV / EBITDA
—
Historical Financials
AKUMS · Annual, last 4 years· amounts in ₹Cr unless noted
| Metric | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | ₹3647 Cr | ₹3475 Cr | ₹4020 Cr | ₹4071 Cr | +3.7% |
| EBITDA | ₹-82.2 Cr | ₹309 Cr | ₹131 Cr | ₹529 Cr | — |
| EBIT | — | — | — | — | — |
| PAT | ₹-253 Cr | ₹94.9 Cr | ₹-4.0 Cr | ₹338 Cr | — |
| EPS (diluted) | — | — | — | — | — |
| CFO | ₹31.9 Cr | ₹177 Cr | ₹498 Cr | ₹465 Cr | +144.4% |
| CapEx | ₹-258 Cr | ₹-329 Cr | ₹-311 Cr | ₹-272 Cr | — |
| FCF | ₹-226 Cr | ₹-152 Cr | ₹187 Cr | ₹193 Cr | — |
| Total Assets | ₹3069 Cr | ₹3267 Cr | ₹3516 Cr | ₹4113 Cr | +10.3% |
| Total Debt | ₹395 Cr | ₹619 Cr | ₹565 Cr | ₹88.2 Cr | -39.3% |
| Shareholders' Equity | ₹625 Cr | ₹723 Cr | ₹720 Cr | ₹3064 Cr | +69.9% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
AKUMS vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| PGHL PROCTER & GAMBLE HEALTH L | -32.5% | 45 | Above Fair Value | 3.1% | — |
| SHILPAMED SHILPAMED | — | — | Pending | 3.3% | — |
| VIYASH VIYASH | — | — | Pending | 2.8% | — |
| STAR STAR | — | — | Pending | 138.9% | — |
| SUDEEPPHRM SUDEEPPHRM | — | — | Pending | 28.1% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for AKUMS in the last 10 years.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. AKUMS DRUGS AND PHARMA L (AKUMS.NS) trades at 514.30 vs a model fair value of 333.47, a gap of -35.2%. Piotroski F-score: 7/9. Moat label...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of AKUMS →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for AKUMS →
Compare
Head-to-head with peers
Compare AKUMS side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse AKUMSNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.